Fixed-dose combinations improve medication compliance: a meta-analysis
- PMID: 17679131
- DOI: 10.1016/j.amjmed.2006.08.033
Fixed-dose combinations improve medication compliance: a meta-analysis
Abstract
Background: Compliance with treatment is a sine qua non for successful treatment of chronic conditions like hypertension. Fixed-dose combinations are designed to simplify the medication regimen and potentially improve compliance. However the data on comparison of fixed-dose combination with free-drug regimen to improve patient's medication compliance is limited.
Methods: We conducted a MEDLINE search of studies using the words fixed-dose combinations, compliance and/or adherence. The inclusion criteria were studies which involved fixed-dose combination versus free-drug components of the regimen given separately. Only studies which reported patient's compliance were included.
Results: Of the 68 studies on fixed-dose combinations, only 9 studies fulfilled the inclusion criteria. Two studies were in patients with tuberculosis, 4 in the hypertensive population, 1 in patients with human immunodeficiency virus (HIV) disease and 2 in the diabetic population. A total of 11,925 patients on fixed-dose combination were compared against 8317 patients on free-drug component regimen. Fixed-dose combination resulted in a 26% decrease in the risk of non-compliance compared with free-drug component regimen (pooled relative risk [RR] 0.74; 95% confidence interval [CI], 0.69-0.80; P <.0001). There was no evidence of heterogeneity in this analysis (chi(2)=14.49, df=8; P=.07). A subgroup analysis of the 4 studies on hypertension showed that fixed-dose combination (pooled RR 0.76; 95% CI, 0.71-0.81; P <.0001) decreased the risk of medication non-compliance by 24% compared with free-drug combination regimen.
Conclusions: Fixed-dose combination decreases the risk of medication non-compliance and should be considered in patients with chronic conditions like hypertension for improving medication compliance which can translate into better clinical outcomes.
Comment in
-
Review: fixed-dose drug combinations improve medication compliance compared with free-drug regimens.Evid Based Med. 2008 Feb;13(1):18. doi: 10.1136/ebm.13.1.18. Evid Based Med. 2008. PMID: 18234926 No abstract available.
Similar articles
-
Real-life treatment patterns, compliance, persistence, and medication costs in patients with hypertension in Germany.J Med Econ. 2012;15(1):155-65. doi: 10.3111/13696998.2011.635229. Epub 2011 Nov 8. J Med Econ. 2012. PMID: 22035215
-
Expanding role of conformulations in the treatment of HIV infection: impact of fixed-dose combinations.AIDS Read. 2004 Oct;14(10):541-3, 547-50. AIDS Read. 2004. PMID: 15510390
-
Adherence with multiple-combination antihypertensive pharmacotherapies in a US managed care database.Clin Ther. 2008 Aug;30(8):1558-63. doi: 10.1016/j.clinthera.2008.08.010. Clin Ther. 2008. PMID: 18803997
-
Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients.Curr Med Res Opin. 2008 Aug;24(8):2389-401. doi: 10.1185/03007990802262457. Epub 2008 Jul 9. Curr Med Res Opin. 2008. PMID: 18616863 Review.
-
Evidence-based interventions to improve patient compliance with antihypertensive and lipid-lowering medications.Int J Clin Pract. 2005 Dec;59(12):1441-51. doi: 10.1111/j.1368-5031.2005.00704.x. Int J Clin Pract. 2005. PMID: 16351677 Review.
Cited by
-
Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study.Cardiovasc Diabetol. 2012 Oct 30;11:134. doi: 10.1186/1475-2840-11-134. Cardiovasc Diabetol. 2012. PMID: 23110471 Free PMC article. Clinical Trial.
-
Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.Am J Clin Nutr. 2012 Feb;95(2):297-308. doi: 10.3945/ajcn.111.024927. Epub 2011 Dec 7. Am J Clin Nutr. 2012. PMID: 22158731 Free PMC article. Clinical Trial.
-
The efficacy and long-term safety of a triple combination of 80 mg telmisartan, 5 mg amlodipine and 12.5 mg hydrochlorothiazide in Japanese patients with essential hypertension: a randomized, double-blind study with open-label extension.Hypertens Res. 2017 Jan;40(1):51-60. doi: 10.1038/hr.2016.100. Epub 2016 Sep 1. Hypertens Res. 2017. PMID: 27581533 Free PMC article. Clinical Trial.
-
Adherence to lipid-lowering treatment: the patient perspective.Patient Prefer Adherence. 2012;6:805-14. doi: 10.2147/PPA.S29092. Epub 2012 Nov 8. Patient Prefer Adherence. 2012. PMID: 23152673 Free PMC article.
-
Two-drug fixed-dose combinations of blood pressure-lowering drugs as WHO essential medicines: An overview of efficacy, safety, and cost.J Clin Hypertens (Greenwich). 2020 Oct;22(10):1769-1779. doi: 10.1111/jch.14009. Epub 2020 Aug 20. J Clin Hypertens (Greenwich). 2020. PMID: 32815663 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous